Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Roadman Investments ( (TSE:LITT) ).
FutureGen Industries reported significant realized gains from several portfolio investments, underscoring the effectiveness of its active management strategy in the healthcare and biotech space. By recycling capital from successful exits, the firm reinforces its ability to fund new opportunities and potentially enhance returns for shareholders, while deepening its exposure to innovative medical technologies.
From a modest $31,175 position in Canadian cancer-therapy developer Onco-Innovations, FutureGen realized gains of about $765,000 after selling 500,000 shares in 2025, highlighting strong value creation in precision oncology. The company also monetized part of its stake in sepsis-focused ASEP Medical Holdings, turning an original Safecoat Medical investment into over $118,000 in gains as ASEP advances rapid diagnostics and peptide-based therapies targeting antibiotic-resistant infections.
FutureGen further booked gains of roughly $167,000 from its indirect investment in psychedelic-drug developer Core One Labs, after its private 1254571 B.C. Ltd. holding converted into COOL shares and milestone-related bonus stock. The exit demonstrates the firm’s willingness to back high-risk, high-potential platforms in psychedelic medicine and then crystallize profits as assets mature, bolstering cash generation while maintaining strategic exposure to frontier biotech fields.
The most recent analyst rating on (TSE:LITT) stock is a Hold with a C$0.29 price target. To see the full list of analyst forecasts on Roadman Investments stock, see the TSE:LITT Stock Forecast page.
Spark’s Take on TSE:LITT Stock
According to Spark, TipRanks’ AI Analyst, TSE:LITT is a Neutral.
The score is held back primarily by weak financial performance—small revenue base, recurring losses, and persistent cash burn with declining equity. Technicals provide some support with price trading above key moving averages and a positive MACD, but valuation remains unattractive due to negative earnings and no indicated dividend yield.
To see Spark’s full report on TSE:LITT stock, click here.
More about Roadman Investments
FutureGen Industries Corp. is a Vancouver-based investment company listed on the TSX Venture Exchange that focuses on identifying and backing emerging life sciences and biotechnology ventures. Its portfolio targets companies developing advanced medical technologies, including precision oncology, infection diagnostics and therapeutics, and psychedelic-based treatments for neurological and mental health conditions. The firm pursues a disciplined, opportunistic strategy aimed at generating value through early-stage and strategic positions across these healthcare niches.
Average Trading Volume: 88,341
Technical Sentiment Signal: Buy
Current Market Cap: C$17.18M
See more insights into LITT stock on TipRanks’ Stock Analysis page.